amyloid

Documents about amyloid

• Amyloid‐related imaging abnormalities (ARIA) in anti‐amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup#125786Europe PMC
• Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM#992435ClinicalTrials.gov
• Early microglial response to amyloid plaques drives sleep loss in Alzheimer's disease#273346Europe PMC
• Study of SOM0226 in Familial Amyloid Polyneuropathy#849818ClinicalTrials.gov
• Return of Amyloid Imaging Results (RAISR Study)#991917ClinicalTrials.gov
• Application of Amyloid PET in Cerebral Amyloid Angiopathy#900392ClinicalTrials.gov
• The amyloid packing difference: a pairwise comparison metric for amyloid structures#170836bioRxiv / medRxiv
• Sleep Quality and Amyloid-Beta Kinetics#908897ClinicalTrials.gov
• Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients#837699ClinicalTrials.gov
• Vyndaqel Capsules Special Investigation (ATTR-CM)#865431ClinicalTrials.gov
• The amyloid packing difference: A pairwise comparison metric for amyloid structures#446717PubMed Central
• Cerebral Infarction and White Substance in Angiopathy Cerebral Amyloid#883985ClinicalTrials.gov
• Differential Synaptic Loss in β‐Amyloid Positive Versus β‐Amyloid Negative Corticobasal Syndrome#463528Apollo
• A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease#855025ClinicalTrials.gov
• PhosphoRus, Proton Imaging and Amyloid BuRdEn (PREPARE) ON AMYLOID BURDEN AND COGNITION#981119ClinicalTrials.gov
• Enpowering Progression Risk of Cerebral Amyloid Angiopathy#844949ClinicalTrials.gov
• F-18-AV-45 Uptake, Spot Sign Presence and Cerebral Amyloid Angiopathy (CAA) in Primary Intracranial Hemorrhage (ICH)#874170ClinicalTrials.gov
• Relationships between longitudinal retinal amyloid imaging and amyloid PET in the A4 Trial.#354641NCBI PubMed Central
• Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain#910854ClinicalTrials.gov
• The Microglial Protein sTREM2 Inhibits the Bacterial Functional Amyloid CsgA and Suppresses Amyloid-Dependent Biofilm Formation#426534bioRxiv / medRxiv
• Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy#847732ClinicalTrials.gov
• Radiolabeled curcumin as β amyloid imaging and tumor targeting imaging agents#932817Jurnal Fitofarmaka Indonesia
• Acute viral encephalitis impacts dense-core amyloid plaque pathology and dysregulates myeloid responses to amyloid plaques.#320396NCBI PubMed Central
• Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy#847001ClinicalTrials.gov
• Positron Emission Tomography of Amyloid in Alzheimer's Disease#847065ClinicalTrials.gov
• Periventricular White Matter Hyperintensities in Cerebral Amyloid Angiopathy and Hypertensive Arteriopathy#991951ClinicalTrials.gov
• Natural History of Amyloid Deposition in Adults With Down Syndrome#811102ClinicalTrials.gov
• Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy#810748ClinicalTrials.gov
• Cerebral Amyloid Imaging Using Florbetapir (AV-45)#828605ClinicalTrials.gov
• Towards anti-biofilm hydrogels targeting bacterial functional amyloid fibrils#235297HAL (France)
• An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy#848382ClinicalTrials.gov
• Amyloid-forming property of the N-terminal 1−70 residues of human apolipoprotein A-IV#481123OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• The Effect of Diflunisal on Familial Amyloidosis#882738ClinicalTrials.gov
• A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)#888757ClinicalTrials.gov
• A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects#802278ClinicalTrials.gov
• Spearmint extract Neumentix downregulates amyloid-β accumulation by promoting phagocytosis in APP23 mice#194771OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Studying the interaction between Polyoxometalates and Amyloid peptides in the context of Alzheimer’s disease#195713HAL (France)
• Purification, crystallization and characterization of the Pseudomonas outer membrane protein FapF, a functional amyloid transporter#474073Spiral
• PL_GNT01_ISR_Grant 53234273#801552ClinicalTrials.gov
• Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage#918378ClinicalTrials.gov
• Dual-action peptide shuttles rescue Cu-amyloid-Β-induced neurotoxicity and relocate Cu intracellularly#202471HAL (France)
• Editorial: Promising therapeutic strategies for Alzheimer’s disease: a focus on amyloid-β targeting#342227IRIS
• Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury#802005ClinicalTrials.gov
• Amyloid Accumulation After Mild Traumatic Brain Injury#902076ClinicalTrials.gov
• Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup.#125278NCBI PubMed Central
• A new era in neuropharmacology: assessing the efficacy and safety of novel anti-amyloid and non-amyloid drug targets for Alzheimer's disease.#159664NCBI PubMed Central
• Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation#869338ClinicalTrials.gov
• Autoxidation Enhances Anti-Amyloid Potential of Flavone Derivatives#933961MIDAS OAI-PMH
• AN INVESTIGATION INTO THE NEUROPROTECTIVE POTENTIAL OF ERGOTHIONEINE IN THE AMYLOID HYPOTHESIS OF ALZHEIMER’S DISEASE#254779ScholarBank@NUS
• A Multidisciplinary Perspective on Research Participation in the Era of Post-Amyloid Disclosure and Disease-Modifying Therapies#289552OSF